Institut Paoli-calmettes

This study tests whether removing the kidney after successful immunotherapy can help patients with metastatic kidney cancer stop all treatment and stay cancer-free. About 60 adults whose tumors have shrunk significantly with immunotherapy will either have surgery and stop therapy…

This study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have strong chemotherapy will take DASATINIB for up to 3 months. Doctors will che…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it works alone or with chemotherapy and another drug. About 27 adults with certain cancers like breast, lung, or stomach cancer…

This study tests whether adults with acute myeloid leukemia (AML) who are doing well on a two-drug chemotherapy combination (venetoclax and azacitidine) can safely stop or reduce their treatment. About 50 participants will stop the drugs and be closely monitored for relapse. Thei…

This study aims to find biological markers (biomarkers) in the blood and tumors of people with non-small cell lung cancer that can predict whether immunotherapy will work. Researchers will compare these markers between people whose cancer responds and those whose does not. The go…